| Trial ID # | NCT02098343 |
| Phase | II |
| Drug Class | Cell Cycle Inhibitors: p53 |
| Drug Name | Eprenetapopt |
| Alternate Drug Names | APR-246, PRIMA-1MET, p53 activator APR-246, PRIMA-1 analogue APR-246 |
| Drugs in Trial | Carboplatin, Liposomal doxorubicin, Eprenetapopt |
| Eligible Participant | TP53-mutated HGS ovarian cancer with disease progression 6-24 months after a first or second Pt-based therapy |
| Patients Enrolled | 200 (Phase Ib: 28) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, evaluated per RECIST |
| Biomarkers | TP53 MUT |
| Efficacy | ORR: 62% (3CR, 10PR, n=21) Exploratory analysis Pt status: |
| Clinically Significant Adverse Events | Serious AE: 1 ruptured diverticulum |
| Conclusion | Encouraging activity in TP53-mutated Pt-S and partially Pt-S patients |
| Reference | Gourley C et al. PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). J Clin Oncol (2016) 34:(suppl; abstr 5571) Basu B et al. PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer. Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.